InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,618.80
(
0.05%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.58
(
-0.35%
)
Bitcoin
62,703.19
(
0.59%
)
Post# of 21373
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zen222

Send PM Follow Ignore
Followers 106
Posts 4156
Boards Moderated 0
Alias Born 03/09/2007

zen222

Re: namtae post# 13658

Tuesday, 11/21/2017 10:57:25 AM

Tuesday, November 21, 2017 10:57:25 AM

Post# of 21373
Like I said, stick around and see for yourself. Patience is a virtue.

Upcoming catalysts include:

Uplisting to OTCQB after new ticker.

Major IR/PR push after ticket change/uplist.

Submission of Prolanta™ for Orphan Designation in the European Union.

The company has identified 2 other drugs that they are looking to acquire.

Adding more prestigious board members and a world-class scientific advisory board.

Clinical results relating to Prolanta™.

MD Anderson will soon evaluate Prolanta™ for the treatment of endometrial cancer.

The company is currently pursuing a licensing partner for Prolanta™ in Asia.

Planning for Nasdaq uplist next year.


Fortes Fortuna Juvat

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up